This product(s) resides on a APICMO contract.
We have the ability to produce, synthesize and manufacture large quantities of 6-Iodo-3h-quinazolin-4-one(16064-08-7) with quality control system under CGMP manufacturing regulations
The 6-Iodoquinazolin-4-one, with the CAS registry number (16064-08-7), is also known as 6-Iodoquinazolin-4(1H)-one. It belongs to the product category of Pharmacetical. this chemical can be prepared by 2-Amino-5-iodo-benzoic acid with Essigsaeure, Formamid. The reaction occurs with reagent ethanol and other condition of heating for 2 hours. The yield is 87 %.New series of 3-(3-trifluoromethylphenyl)-6-iodo-4(3H)-quinazolinone derivatives bearing thiosemicarbazones, pyrazoles, azomethine moieties at C-2 were synthesized. The obtained products were screened for their expected anticancer activity against; human liver cancer cell line (HepG2), breast cancer cell line (MCF-7) and human lung adenocarcinoma epithelial cell line (A549) tumor cell lines. Cytotoxicity of the synthesized compounds showed good IC50 for some products in comparison with the standard drug, doxorubicin. On the other hand, antiviral activity of the synthesized products against H5N1 showed moderate to weak activity compared to Zanamivir reference drug. 2-Aminoquinazolin-4(3H)-ones were previously discovered as perspective leads for antimalarial drug development targeting the plasmepsins. Here we report the lead optimization studies with the aim to reduce inhibitor lipophilicity and increase selectivity versus the human aspartic protease Cathepsin D. Exploiting the solvent exposed area of the enzyme provides an option to install polar groups (R1) the 5-position of 2-aminoquinazolin-4(3H)-one to inhibitors such as carboxylic acid without scarifying enzymatic potency. Moreover, introduction of R1 substituents increased selectivity factors of compounds in this series up to 100-fold for Plm II, IV vs CatD inhibition. The introduction of flap pocket substituent (R2) at 7-postion of 2-aminoquinazolin-4(3H)-one allows to remove Ph group from THF ring without notably impairing Plm inhibitory potency. Based on these findings, inhibitors were developed, which show Plm II and IV inhibitory potency in low nanomolar range and remarkable selectivity against Cathepsin D along with decreased lipophilicity and increased solubility.Among the 3-(2,6-dimethylphenyl)quinazolinone series, the introduction of an indol-5-yl substituent at the pyrazolo[3,4-d]pyrimidine 3-position led to a potent and selective PI3Kδ (IC50 = 8.6 nM) inhibitor 10d, that was more than 3630-fold, 390-fold and 40-fold selective for PI3Kδ over PI3Kα β and γ while the substitution with a 3,4-dimethoxyphenyl resulted in a potent and selective dual PI3Kδ/γ inhibitor 10e with IC50 values of 8.4 nM and 62 nM against PI3Kδ and PI3Kγ respectively. Compound 10e was also more than 1400-fold, 820-fold selective for PI3Kδ over PI3Kα and PI3Kβ. In agreement with their remarkable PI3Kδ inhibitory activity, compounds 10d and 10e showed high antiproliferative activity against human B-cell SU-DHL-6 cells. Moreover, the dual PI3Kδ/γ inhibitor 10e had reasonable pharmacokinetic profiles with a good plasma exposure, low clearance, low volume distribution, and an acceptable oral bioavailability of 34.9percent.
|CAS Min %||95.0|
|CAS Max %||100.0|
|Chemical Name or Material||6-Iodo-3h-quinazolin-4-one|
|Molecular Weight (g/mol)||272.04|
|Color||Very Pale Yellow Red-Greyish Red|
6-Iodo-3h-quinazolin-4-one(16064-08-7) Safety and Handling
(16064-08-7) Hazard description:
◆Causes skin irritation.
◆Causes serious eye irritation.
◆May cause respiratory irritation.
(16064-08-7) Precautionary statement:
◆Avoid breathing dust/fume/gas/mist/vapors/spray.
◆Wear protective gloves/protective clothing/eye protection/face protection.
◆IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
◆IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing.
◆Store locked up.
◆Dispose of contents/container in accordance with local/regional/national/international regulations.
WARNING: The information provided on this web site was developed in compliance with European Union (EU) regulations and is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guide for safe handling and use. It is not to be considered as either a warranty or quality specification.
New series of 4(3H)-quinazolinone derivatives: syntheses and evaluation of antitumor and antiviral activities
New series of 3-(3-trifluoromethylphenyl)-6-iodo-4(3H)-quinazolinone derivatives bearing thiosemicarbazones, pyrazoles, azomethine moieties at C-2 were synthesized…
Medicinal Chemistry Research 2018 vol. 27 # 2 p. 571 – 582,
Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors
PI3Kδ and PI3Kγ regulate immune cell signaling. Selective PI3Kδ or PI3Kγ inhibitors and dual PI3Kδ/γ inhibitors have the potential for the treatment of immune cell-mediated diseases and hematological malignancies…
European Journal of Medicinal Chemistry 2018 vol. 151 p. 9 – 17,
6-Iodo-3h-quinazolin-4-one(16064-08-7) Technical Service:
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
6-Iodo-3h-quinazolin-4-one(16064-08-7) Bulk Ordering & Pricing:
Need larger quantities for your development, manufacturing or research applications?